<bill session="111" type="h" number="3475" updated="2023-01-11T13:18:22Z">
  <state datetime="2009-07-31">REFERRED</state>
  <status>
    <introduced datetime="2009-07-31"/>
  </status>
  <introduced datetime="2009-07-31"/>
  <titles>
    <title type="display">Accelerate Cures for Patients Act of 2009</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to double the amount of funds authorized to be appropriated to the National Institutes of Health for medical research with the greatest potential for near-term clinical benefit.</title>
    <title type="short" as="introduced">Accelerate Cures for Patients Act of 2009</title>
  </titles>
  <sponsor bioguide_id="F000445"/>
  <cosponsors/>
  <actions>
    <action datetime="2009-07-31">
      <text>Introduced in House</text>
    </action>
    <action datetime="2009-07-31" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2009-09-08">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Department of Health and Human Services"/>
    <term name="Executive agency funding and structure"/>
    <term name="Health programs administration and funding"/>
    <term name="Medical research"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Research administration and funding"/>
  </subjects>
  <amendments/>
  <summary date="2010-03-17T18:31:59Z" status="Introduced in House">Accelerate Cures for Patients Act of 2009 - Amends the Public Health Service Act to authorize additional appropriations to the National Institutes of Health (NIH) to conduct or support medical research that relates to cancer, cardiovascular disease, diabetes, Alzheimer's disease, Parkinson's disease, or other diseases or conditions and that has the greatest potential for near-term clinical benefit in human patients, as indicated by substantial evidence from basic research or by substantial clinical evidence. Allows such evidence to include: (1) evidence of improvement in one or more human patients suffering from illness or injury, as documented in reports by professional medical or scientific associations or in peer-reviewed medical or scientific literature; and (2) approval for use in human trials by the Food and Drug Administration (FDA).</summary>
</bill>
